The FDA-approved drug tilmanocept, which is a DTPA-mannosyl-dextran, was recently investigated for targeting CD206 and SPECT imaging of bleomycin-induced lung fibrosis and in ex vivo lung biopsies illustrating the utility of CD206 imaging in fibrosis [7]. This evidence concerns the gene MRC1 and pulmonary fibrosis.